BioLife Solutions Inc. (BLFS)
BioLife Solutions Inc. (BLFS) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | 1.71B |
| Revenue (ttm) | 106.69M |
| Net Income (ttm) | 49.21M |
| Beta | 1.90 |
| EPS (ttm) | 1 |
| PE Ratio (ttm) | 34.94 |
| Forward PE | 105.88 |
| P/B (ttm) | 4.53 |
| P/S (ttm) | 16.02 |
| Earnings Date | Aug 12, 2021 |
| Ask | n/a |
| Volume | 389,451 |
| Avg. Volume (20D) | 1,111,888 |
| Open | 35.24 |
| Previous Close | 35.45 |
| Day's Range | 34.76 - 35.24 |
| 52-Week Range | 17.86 - 35.46 |
| Analyst | Hold |
| Price Target | 31 (-11.28%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BLFS
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media ...
Financial Performance
In 2025, BioLife Solutions's revenue was 96.21M, an increase of 28.89% compared to the previous year's 74.65M. Earnings were -4.59M, a decrease of -77.23%.
Financial StatementsAnalyst Forecast
According to 7 analyst ratings, the average rating for BLFS stock is "Hold". The 12-month stock price forecast is 31, which is downside of 11.28% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
